A new boron compound (guanidine biboric acid adduct) as an antitumour agent against Ehrlich ascites carcinoma in mice.
The inhibitory effects of a new boron compound of guanidine biboric acid adduct (GB) and guanidium chloride (L1) on the growth of ascites tumour in female Swiss mice were studied by monitoring the survival, tumour weight, tumour cell count, transplantability of Ehrlich ascites cells, precursor incorporation and the haematological parameters of the treated mice. 5-Fluorouracil, a known anticancer drug, was used as a positive control. The most important parameter was the survival time, which increased significantly when tumour-bearing mice were treated with the boron compound. Haematological parameters of the treated animals showed minimum toxic effects when boron was coupled with guanidine.
Ghosh
P
P
Department of Chemistry, Jadavpur University, Calcutta, India.
Sur
B
B
Bag
S P
SP
Sur
P
P
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001888:Boric Acids / Q000494:pharmacology*; D001896:Boron Compounds; D002286:Carcinoma, Ehrlich Tumor / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D019791:Guanidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006146:Guanidines; D007928:Lethal Dose 50; D007958:Leukocyte Count / Q000187:drug effects; D051379:Mice; D009368:Neoplasm Transplantation
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001888:Boric Acids; D001896:Boron Compounds; D004273:DNA, Neoplasm; D006146:Guanidines; C117044:guanidine biboric acid adduct; D019791:Guanidine; D005472:Fluorouracil